In a report released yesterday, Phil Nadeau from Cowen & Co. maintained a Buy rating on Atreca Inc (BCEL). The company’s shares closed last Monday at $14.49.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 4.5% and a 47.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
Atreca Inc has an analyst consensus of Strong Buy, with a price target consensus of $25.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20 and a one-year low of $10.29. Currently, Atreca Inc has an average volume of 145.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response.
